Outputs (2)

DYNamic Assessment of Multi‐Organ level dysfunction in patients recovering from COVID‐19: DYNAMO COVID‐19 (2024)
Journal Article
Gupta, A., Nicholas, R., McGing, J. J., Nixon, A. V., Mallinson, J. E., McKeever, T. M., Bradley, C. R., Piasecki, M., Cox, E. F., Bonnington, J., Lord, J. M., Brightling, C. E., Evans, R. A., Hall, I. P., Francis, S. T., Greenhaff, P. L., & Bolton, C. E. (2024). DYNamic Assessment of Multi‐Organ level dysfunction in patients recovering from COVID‐19: DYNAMO COVID‐19. Experimental Physiology, 109(8), 1274-1291. https://doi.org/10.1113/ep091590

We evaluated the impacts of COVID-19 on multi-organ and metabolic function in patients following severe hospitalised infection compared to controls. Patients (n = 21) without previous diabetes, cardiovascular or cerebrovascular disease were recruited... Read More about DYNamic Assessment of Multi‐Organ level dysfunction in patients recovering from COVID‐19: DYNAMO COVID‐19.

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea (2013)
Journal Article
Garsed, K., Chernova, J., Hastings, M., Lam, C., Marciani, L., Singh, G., Henry, A. P., Hall, I. P., Whorwell, P., & Spiller, R. C. (2014). A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut, 63(10), 1617-1625. https://doi.org/10.1136/gutjnl-2013-305989

Background: Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) have proven effective but have serious side effects.... Read More about A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.